P

    ProMIS Neurosciences Inc. (PMN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.07
    -0.72 (-5.19%)

    Market Cap: $123.62M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(24/30)
    Avg Surprise
    -1.29%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.82
    Range$-1.85 - $-1.79
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-2.15-17.8%
    7d ago$-2.13-16.8%
    Current$-1.82
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Dec 31, 2026
    EPS Consensus$-2.17
    Range$-2.30 - $-2.04
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.17---
    Sep 26EST
    		-$-1.82---
    Jun 26
    		$-1.28$-1.45+11.72%Beat+87.2%
    Mar 26
    		$-1.26$-0.20-516.10%Miss+82.8%
    Dec 25
    		$-30.05$-6.71-347.84%Miss-25141.7%
    Sep 25
    		$-8.40$-9.99+15.92%Beat-177.3%
    Jun 25
    		$-9.98$-6.04-65.23%Miss-123.3%
    Mar 25
    		$-7.35$-4.30-70.93%Miss-13.4%
    Dec 24
    		$0.12$-0.16+175.00%Beat+141.4%
    Sep 24
    		$10.86$-2.42+548.76%Beat+266.6%
    Jun 24
    		$-4.47$-4.85+7.84%Beat-1555.6%
    Mar 24
    		$-6.48$-6.87+5.68%Beat-1020.9%
    Dec 23
    		$-0.29$-0.27-7.41%Miss+75.2%
    Sep 23
    		$-6.52$-11.42+42.91%Beat-487.4%
    Jun 23
    		$-0.27$-0.27+0.00%Beat+43.7%
    Mar 23
    		$-0.58$-0.58+0.33%Beat+3.7%
    Dec 22
    		$-1.17N/AN/ABeat-262.8%
    Sep 22
    		$-1.11$-0.85-30.59%Miss-760.5%
    Jun 22
    		$-0.48N/AN/ABeat-910.5%
    Mar 22
    		$-0.60N/AN/ABeat+51.0%
    Dec 21
    		$-0.32N/AN/ABeat-195.6%
    Sep 21
    		$-0.13N/AN/ABeat+78.5%
    Jun 21
    		$-0.05N/AN/ABeat+92.1%
    Mar 21
    		$-1.22$-1.49+17.83%Beat-12144.0%
    Dec 20
    		$-0.11N/A+75.76%Beat-991.0%
    Sep 20
    		$-0.60$-0.60+0.00%Beat-5900.0%
    Jun 20
    		$-0.60$-0.60+0.00%Beat-5900.0%
    Mar 20
    		$-0.01N/A+97.67%Beat+0.0%
    Dec 19
    		$-0.01$-0.01+0.00%Beat+0.0%
    Sep 19
    		$-0.01$-0.01+0.00%Beat+0.0%
    Jun 19
    		$-0.01$-0.01+0.00%Beat+0.0%
    Mar 19
    		$-0.01$-0.01+0.00%Beat+0.0%
    Dec 18
    		$-0.01$-0.01+0.00%Beat+0.0%
    Sep 18
    		$-0.01$-0.01+0.00%Beat+0.0%
    Jun 18
    		$-0.01$-0.01+0.00%Beat+97.6%
    Mar 18
    		$-0.01$-0.01+0.00%Beat+96.9%
    Dec 17
    		$-0.01$-0.01+0.00%Beat+96.7%
    Sep 17
    		$-0.01$-0.01+0.00%Beat+95.6%
    Jun 17
    		$-0.42N/AN/ABeat-
    Mar 17
    		$-0.32N/AN/ABeat-
    Dec 16
    		$-0.30N/AN/ABeat-
    Sep 16
    		$-0.23N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.32EV/EBITDA-1.74x
    Price/FCF-2.84xFCF Yield-35.24%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-172.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage37.20x
    Current Ratio7.85xQuick Ratio7.85x
    Trading Statistics
    Beta-0.22Avg Volume27.54K
    52-Week High$27.4052-Week Low$6.27

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.45
    SMA 20$14.41
    SMA 50$13.62
    SMA 200$12.37
    EMA 10$14.19
    EMA 20$14.24
    EMA 50$13.64
    EMA 200$12.99

    MACD

    Line: 0.10Signal: 0.33Hist: -0.23

    ADX

    ADX: 37.1+DI: 18.6-DI: 14.4

    Aroon & PSAR

    Aroon Up4.0
    Aroon DownN/A
    PSAR$17.17

    Bollinger Bands

    Upper Band$15.68
    Lower Band$13.13
    %B Position1770%(Upper)
    Band Width-0.02

    RSI (14-Day)

    Neutral
    41.8

    Momentum Oscillators

    Stoch %K6.3
    Stoch %D22.4
    Williams %R-100.0
    ROC (10d)-10.8%
    Momentum-1.59
    CCI (20d)-146.5
    MFI (14d)50.5

    Volatility Measures

    ATR (14d)$1.14(8.8%)
    StdDev (20d)0.64
    Hist Vol58.0%(High)

    Volume Flow

    VWAP$13.49
    OBV330.7M
    AD Line80.0B
    CMF (20d)0.068

    Volume Metrics

    Avg Vol (20d)28.0K
    Vol Ratio0.9x
    VWMA (20d)$14.44

    Pivot Points

    R3$15.56
    R2$15.08
    R1$14.43
    Pivot Point$13.95
    S1$13.30
    S2$12.82
    S3$12.17

    Advanced Oscillators

    TSI3.12
    Ultimate Osc34.9
    KST56.75

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0$4.32M$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0$-4,320,498$0$0$0N/A$0
    Operating Expenses$12.27M$8.64M$10.77M$11.75M$10.18M$7.46M$6.00M$4.43M$2.71M$3.68M$3.87M$2.52M
    R&D$9.52M$6.97M$9.37M$9.80M$8.75M$5.46M$4.32M$2.56M$1.63M$2.12M$2.23M$1.14M
    SG&A$2.74M$1.67M$1.40M$1.95M$1.43M$2.00M$1.68M$1.87M$1.09M$1.55M$1.65M$1.38M
    Operating Income$-12,266,399$-8,644,895$-10,772,120$-11,750,432$-10,184,661$-7,460,095$-6,002,444$-4,434,677$-2,713,706$-3,676,651$-3,874,638$-2,517,540
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$76,775$76,795$75,413
    Income Before Tax$-11,729,656$-8,244,372$-10,679,681$-11,580,126$-10,117,029$-7,347,903$-238,207$9.28M$-2,623,657$-3,635,088$-4,006,997$-2,360,648
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-11,729,656$-8,244,372$-10,674,089$-11,580,126$-10,117,029$-7,347,903$-238,207$9.28M$-2,623,657$-3,635,088$-3,580,429$-2,360,648
    EBITDA$-11,729,656$-8,244,372$-10,679,681$-11,580,126$-10,117,029$-7,347,903$-238,207$9.28M$-2,623,657$-3,558,313$-3,912,181$-2,284,890
    EBIT$-11,729,656$-8,244,372$-10,679,681$-11,580,126$-10,117,029$-7,347,903$-238,207$9.28M$-2,623,657$-3,558,313$-3,930,202$-2,285,235
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PMN

    News

    ProMIS Neurosciences (Nasdaq:PMN) - Stock Analysis

    This Simply Wall St analysis provides an overview of ProMIS Neurosciences (PMN), highlighting its market cap of US$130.1m and recent performance. The article details the company's lead drug candidate, PMN310, for Alzheimer's disease, including positive interim safety and biomarker data from its Phase 1b trial and previous human evidence of target engagement. It also discusses various financial risks such as declining earnings forecasts, shareholder dilution, and a low market capitalization.

    Simply Wall Street•8/23/26•
    Somewhat-Bullish

    Q3 EPS Estimates for PMN Raised by Brookline Capital Markets

    Brookline Capital Markets has raised its Q3 2026 EPS forecast for Promis Neurosciences (NASDAQ:PMN) to a loss of $1.29 per share from a previous estimate of $2.41, while maintaining a "Strong Buy" rating. The company recently reported a quarterly loss of $1.28 per share, outperforming the consensus estimate. Promis Neurosciences currently holds a "Moderate Buy" consensus rating among analysts with an average target price of $31.50.

    MarketBeat•8/19/26•
    Bullish

    ProMIS Neurosciences (PMN): Great Point group reports 7.66% beneficial stake

    Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, have reported a 7.66% beneficial ownership stake in ProMIS Neurosciences Inc. This ownership includes 736,881 common shares, encompassing shares underlying warrants, and is calculated against a total of 9,618,424 outstanding shares. The reporting group holds shared voting and dispositive power over these shares, with their holdings primarily channeled through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd.

    Stock Titan•8/14/26•
    Neutral

    Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

    Guggenheim raised its price target for Promis Neurosciences (NASDAQ:PMN) from $69 to $100, maintaining a "Buy" rating, while other analysts have varied ratings but a consensus "Moderate Buy" with a $39.25 target. The clinical-stage biopharmaceutical company's shares opened at $14.93, with a market capitalization of $133.9 million, and recently reported better-than-expected quarterly earnings. Institutional investors collectively own 50.13% of the company's stock.

    MarketBeat•8/14/26•
    Neutral

    ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside

    ProMIS Neurosciences Inc. (PMN) has seen its 12-month average price target raised by analysts from $39.21 to $43.64, with forecasts ranging from $18 to $100 per share. This new target suggests a potential upside of approximately 195% based on the August 13 closing price. The consensus rating from 8 covering analysts remains a "Buy."

    TradingView•8/14/26•
    Bullish

    Frequently Asked Questions About PMN

    Does PMN pay dividends?
    ProMIS Neurosciences Inc. (PMN) does not currently pay a regular dividend.
    What is PMN's market cap?
    ProMIS Neurosciences Inc. (PMN) has a market capitalization of $123.62M with a current stock price of $13.07.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In